This opens a possible therapeutic window beyond the use of PARPi, and expands the therapeutic landscape to those anti-tumor agents able to inhibit key mediators of DNA repair and replication, including Chk1 and Wee1 (38, 39). This evidence concerns the gene WEE1 and neoplasm.